115 related articles for article (PubMed ID: 8330994)
1. Halogenated pyrimidine sensitization of low dose rate irradiation in human malignant glioma.
McLaughlin PW; Mancini WR; Stetson PL; Greenberg HS; Nguyen N; Seabury H; Heidorn DB; Lawrence TS
Int J Radiat Oncol Biol Phys; 1993 Jul; 26(4):637-42. PubMed ID: 8330994
[TBL] [Abstract][Full Text] [Related]
2. Bromodeoxyuridine-mediated radiosensitization in human glioma: the effect of concentration, duration, and fluoropyrimidine modulation.
McLaughlin PW; Lawrence TS; Seabury H; Nguyen N; Stetson PL; Greenberg HS; Mancini WR
Int J Radiat Oncol Biol Phys; 1994 Oct; 30(3):601-7. PubMed ID: 7928491
[TBL] [Abstract][Full Text] [Related]
3. Low dose rate irradiation and halogenated pyrimidine effects on human cervical carcinoma cells.
Tishler RB; Geard CR
Int J Radiat Oncol Biol Phys; 1991 Sep; 21(4):975-82. PubMed ID: 1917628
[TBL] [Abstract][Full Text] [Related]
4. Sensitization of radiolabeled monoclonal antibody therapy using bromodeoxyuridine.
Buchsbaum DJ; Khazaeli MB; Davis MA; Lawrence TS
Cancer; 1994 Feb; 73(3 Suppl):999-1005. PubMed ID: 8306292
[TBL] [Abstract][Full Text] [Related]
5. BrdUrd-induced radiosensitization of two human tumour cell lines at iso-levels of incorporation.
Franken NA; Van Bree C; Kipp JB; Rodermond HM; Haveman J; Barendsen GW
Oncol Rep; 2000; 7(5):937-40. PubMed ID: 10948317
[TBL] [Abstract][Full Text] [Related]
6. The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure.
Lawrence TS; Davis MA; Maybaum J; Stetson PL; Ensminger WD
Int J Radiat Oncol Biol Phys; 1990 Jun; 18(6):1393-8. PubMed ID: 2370189
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo radiation sensitization by the halogenated pyrimidine 5-chloro-2'-deoxycytidine.
Russell KJ; Rice GC; Brown JM
Cancer Res; 1986 Jun; 46(6):2883-7. PubMed ID: 3698014
[TBL] [Abstract][Full Text] [Related]
8. Treatment of intracranial rat glioma model with implant of radiosensitizer and biomodulator drug combined with external beam radiotherapy.
Li Y; Owusu A; Lehnert S
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):519-27. PubMed ID: 14751523
[TBL] [Abstract][Full Text] [Related]
9. Tumour radiosensitization with the halogenated pyrimidines 5'-bromo- and 5'-iododeoxyuridine.
Epstein AH; Cook JA; Goffman T; Glatstein E
BJR Suppl; 1992; 24():209-14. PubMed ID: 1290703
[No Abstract] [Full Text] [Related]
10. The effects of pentoxifylline on the survival of human glioma cells with continuous and intermittent stereotactic radiosurgery irradiation.
Eley KW; Benedict SH; Chung TD; Kavanagh BD; Broaddus WC; Schmidt-Ullrich RK; Lin PS
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):542-50. PubMed ID: 12243834
[TBL] [Abstract][Full Text] [Related]
11. Protracted exposure radiosensitization of experimental human malignant glioma.
Williams JA; Williams JR; Yuan X; Dillehay LE
Radiat Oncol Investig; 1998; 6(6):255-63. PubMed ID: 9885941
[TBL] [Abstract][Full Text] [Related]
12. Effect of subsequent acute-dose irradiation on cell survival in vitro following low dose-rate exposures.
Mitchell CR; Joiner MC
Int J Radiat Biol; 2002 Nov; 78(11):981-90. PubMed ID: 12456285
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of X ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs.
Kinsella TJ; Dobson PP; Mitchell JB; Fornace AJ
Int J Radiat Oncol Biol Phys; 1987 May; 13(5):733-9. PubMed ID: 3570896
[TBL] [Abstract][Full Text] [Related]
14. Variability of 5-bromo-2'-deoxyuridine incorporation into DNA of human glioma cell lines and modulation with fluoropyrimidines.
Mancini WR; Stetson PL; Lawrence TS; Wagner JG; Greenberg HS; Ensminger WD
Cancer Res; 1991 Feb; 51(3):870-4. PubMed ID: 1824826
[TBL] [Abstract][Full Text] [Related]
15. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma.
Prados MD; Scott CB; Rotman M; Rubin P; Murray K; Sause W; Asbell S; Comis R; Curran W; Nelson J; Davis RL; Levin VA; Lamborn K; Phillips TL
Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):653-9. PubMed ID: 9486616
[TBL] [Abstract][Full Text] [Related]
16. The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer.
Lawrence TS; Davis MA; Maybaum J; Mukhopadhyay SK; Stetson PL; Normolle DP; McKeever PE; Ensminger WD
Cancer Res; 1992 Jul; 52(13):3698-704. PubMed ID: 1617642
[TBL] [Abstract][Full Text] [Related]
17. Correlation of sensitizer enhancement ratio with bromodeoxyuridine concentration and exposure time in human cervical carcinoma cells treated with low dose rate irradiation.
Tishler RB; Geard CR
Int J Radiat Oncol Biol Phys; 1992; 22(3):495-8. PubMed ID: 1735686
[TBL] [Abstract][Full Text] [Related]
18. The effect of single versus double-strand substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells.
Lawrence TS; Davis MA; Maybaum J; Stetson PL; Ensminger WD
Radiat Res; 1990 Aug; 123(2):192-8. PubMed ID: 2389005
[TBL] [Abstract][Full Text] [Related]
19. IUdR polymers for combined continuous low-dose rate and high-dose rate sensitization of experimental human malignant gliomas.
Yuan X; Dillehay LE; Williams JR; Shastri VR; Williams JA
Int J Cancer; 2001 Apr; 96(2):118-25. PubMed ID: 11291095
[TBL] [Abstract][Full Text] [Related]
20. The biological effect of pentoxifylline on the survival of human head and neck cancer cells treated with continuous low and high dose-rate irradiation.
Danielsson A; Karlsson E; Delle U; Helou K; Mercke C
J Cancer Res Clin Oncol; 2005 Jul; 131(7):459-67. PubMed ID: 15776273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
